Global Primary Biliary Cholangitis Therapeutics Market to Grow by USD 241.28 Million during 2019-2023 | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–Technavio’s latest market research report on the global primary biliary
cholangitis therapeutics market predicts the market to witness a CAGR of
close to 10% during the forecast period. This research report segments
the market by product (OCALIVA, ursodiol, and others) and geography
(North America, Europe, Asia, and ROW).

Advent of regenerative therapy

The recurring nature of primary biliary cholangitis is one of the major
challenges faced in the global market. As currently there is no cure for
the indication except for liver transplantation, the market witnesses a
need for curative therapy. As a result, various researchers are
conducting studies on developing regenerative therapies that could
ensure the complete remission of the indication to overcome this
challenge and capture the huge unmet need. Although the research on the
use of stem cell transplantation is still in the nascent stages, and the
mechanism of the therapy is still not known to the researchers, advances
stem cell transplantation are expected to add significant value to the global
primary biliary cholangitis market growth during the
forecast period.

OCALIVA product segment will garner the highest share

OCALIVA was the largest segment of the global primary biliary
cholangitis therapeutics market in 2018 and is expected to grow faster
than the overall market during the forecast period. OCALIVA was
developed for the treatment of various liver-related indications, with
primary biliary cholangitis being the main indication. It is currently
the most preferred drug for the treatment of the indication due to its
strong efficacy to target the T-cells that are known to cause primary
biliary cholangitis. As a result, the adoption of OCALIVA is expected to
increase significantly during the next five years.

“The treatment using OCALIVA has provided positive results. Moreover,
the side effects associated with the use of OCALIVA are milder than
other drugs such as URSO 250 and URSO Forte. The risk of possible side
effects of OCALIVA can also be decreased by changing the dosage or the
duration of the drug, which will further contribute to the growing
demand for this drug globally,” says a senior research analyst at
Technavio

Looking for more information on this market? Request
a free sample report

Primary biliary cholangitis therapeutics to witness fastest adoption
in Europe.

Europe is expected to emerge as the fastest growing region of the global
primary biliary cholangitis therapeutics market during the forecast
period owing to the increasing prevalence and the incidence of the
indication in most developed countries in this region. The advanced
healthcare infrastructure in the region is also helping in overcome the
challenges associated with the diagnosis and the treatment of the
indication. Furthermore, growing awareness about the disease due to
initiatives taken by various vendors and other organizations are
expected to drive the growth of the primary biliary cholangitis
therapeutics market in the region.

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the global
primary biliary cholangitis therapeutics market analysis include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio
is a leading global technology research and advisory company. It
provides detailed market research reports that provide clients with
actionable insights to help them identify market opportunities and
design effective strategies to optimize their market position.

With over 500 specialized analysts, Technavio boasts of an extensive
report library comprising of over 10,000 reports, covering 800
technologies, spanning across 50 countries. Their client base consists
of enterprises of all sizes, including more than a hundred Fortune 500
companies. This growing client base relies on Technavio’s comprehensive
coverage, extensive research, and actionable market insights to identify
opportunities in existing and potential markets. Technavio helps
companies to assess their competitive position within changing market
scenarios.

If you are interested in more information, please contact our media team
at [email protected].

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com